Tag - EFTR

Markets

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast cancer

Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...

May 26, 2023

Markets

Cantor starts eFFECTOR Therapeutics at OW; PT $50

Cantor Fitzgerald launched coverage of eFFECTOR Therapeutics (NASDAQ:EFTR) with an “overweight” rating and price target of $50. The stock closed at $26.59 on Sept. 10. eFFECTOR is focused on developing a new class of...

September 13, 2021

Tag - EFTR

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast cancer

Cantor starts eFFECTOR Therapeutics at OW; PT $50

General

More